Retatrutide's Phase 2 trial data (Jastreboff et al., NEJM 2023) identified a side-effect profile broadly consistent with other incretin-based therapies: Gastrointestinal : Nausea, vomiting, diarrhoea, and constipation were the most commonly reported adverse effects, particularly during dose escalation
Ideal for: Healthcare workers at ETSU Health, Ballad Health, or local clinics Anyone prone to frequent infections Those recovering from illness Chronic immune conditions Seasonal immune support Popular Peptide Treatments at Peak Performance BPC-157: The Healing Powerhouse Known for remarkable healing properties, BPC-157 excels at repairing muscles, tendons, ligaments, and even gut health
I am excited to start my treatments here
Ideal for off-cycle healing or athletes under heavy training volume
The riddle of nonalcoholic fatty liver disease: Progression from nonalcoholic fatty liver to nonalcoholic Steatohepatitis (in Eng)